← Back to all signals
RESEARCH PAPER ANALYSIS

Cholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's disease.

AI interpretation is pending for this paper.

PMID42199104
JournalNeural regeneration research
Publication Date2026-05-14
Ingested2026-05-27 06:55 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Brain cholinergic systems changes are implicated in the pathophysiology of postural instability and gait difficulties in Parkinson's disease. The presence of postural instability and gait difficulties is associated with cholinergic terminal deficits or downregulation of cholinergic neurotransmission. Preservation or upregulation of cholinergic neurotransmission may mitigate other Parkinson's disease-associated deficits to prevent postural instability and gait difficulties that are dependent on effective sensorimotor, cognitive, and emotional integration functions. Emerging evidence also suggests that dopaminergic neurotransmission is up- and downregulated in extra-striatal regions. This expanded view of complex whole brain up and downregulatory cholinergic and dopaminergic interactive processes requires a re-appraisal of pathophysiologic changes underlying mobility disturbances in Parkinson's disease. The goal of this review is to propose a novel expanded heuristic model of dynamic cholinergic and dopaminergic systems changes underlying habitual and goal-directed motor behaviors in Parkinson's disease. We hypothesize a hierarchical topographic whole-brain model where variable combinations of up- and down-regulation of cholinergic and dopaminergic neurotransmission differentially explain habitual and goal-directed motor behavior abnormalities underlying axial motor impairments. We propose that levodopa-unresponsive freezing of gait is the culmination of combined cholinergic and dopaminergic losses in selective thalamic, (para-) limbic, thalamic complex, upper tectum, upper tegmental (especially periaqueductal gray), and cerebellar brain regions. This model is based on a comparison of literature findings of cholinergic topographic deficits underlying postural instability and gait difficulties motor findings, complemented by emerging and preliminary evidence of extra-striatal dopaminergic system changes across the spectrum of Parkinson's disease. In contrast, different topographic cholinergic system deficits, associated with freezing of gait, such as the mesencephalic and cerebellar locomotor regions, diffuse striatal, and peri-central cortices - that are key pathways of dopaminergic-dependent habitual motor behaviors - are seen with levodopa-responsive but not with unresponsive freezing of gait. Cholinergic upper tegmental, including periaqueductal gray, and limbic deficits associated with levodopa-unresponsive freezing of gait also plays a role in emotional regulation. Failure of this circuitry may lead to a context-dependent downward spiral of fear of falling, which in turn compromises the motivation to move and worsens or triggers levodopa-unresponsive freezing of gait. Cholinergic losses in the periaqueductal gray upper tegmental region may acutely block goal-directed motor behavior, contributing to the panic disorder subtype of freezing of gait. Such a freezing of gait subtype may be a naturally protective defense mechanism that, in the context of the high inherent risk of freezing of gait-associated falling, becomes counterproductive. Future research should test this heuristic model.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic